Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Calcium antagonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Calcium antagonist. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-015247-16 Sponsor Protocol Number: 162 Start Date*: 2010-10-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg...
    Medical condition: Primary Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Completed) FI (Completed) PT (Completed) DE (Completed) DK (Completed) SE (Completed) LT (Completed) EE (Completed) SI (Completed) SK (Completed) NL (Completed) CZ (Completed) BG (Completed) IT (Completed) HU (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-018215-53 Sponsor Protocol Number: AFRODITE Start Date*: 2010-02-10
    Sponsor Name:sanofi-aventis Netherlands
    Full Title: The effect of the addition of dronedarone to, versus increase of, existing conventional rate control medication on ventricular rate during paroxysmal or persistent atrial fibrillation (AFRODITE study)
    Medical condition: atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    12.1 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001761-11 Sponsor Protocol Number: 300488 Start Date*: 2015-08-31
    Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital
    Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women
    Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004867 10067033 Drug side effect LLT
    18.0 100000004867 10034570 Peripheral edema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006246-34 Sponsor Protocol Number: CL3-16257-068 Start Date*: 2007-11-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in pa...
    Medical condition: Stable angina pectoris
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) EE (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002439-33 Sponsor Protocol Number: MeIn/08/ZOF+HCTZ-HYP/001 Start Date*: 2008-06-26
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY
    Medical condition: Patients with essential hypertension and with at least one additional cardiovascular risk factor, not controlled by a previous monotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) LT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005432-32 Sponsor Protocol Number: 08.0113 Start Date*: 2009-06-02
    Sponsor Name:St. George's University of London (SGUL)
    Full Title: Effects of an Angiotensin Receptor Antagonist Candesartan versus a calcium channel blocker Amlodipine on Microvascular Rarefaction, Endothelial Dysfunction and Microalbuminuria in Essential Hyperte...
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10004254 Benign essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000749-13 Sponsor Protocol Number: SPON CU 101 Start Date*: 2005-07-30
    Sponsor Name:Cardiff University
    Full Title: A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.
    Medical condition: Marfan Syndrome
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003482-68 Sponsor Protocol Number: BAY 63-2521/12934 Start Date*: 2008-11-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005485-37 Sponsor Protocol Number: 20050147 Start Date*: 2006-06-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) CZ (Completed) BE (Completed) IE (Completed) SK (Completed) HU (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) LT (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001412-38 Sponsor Protocol Number: CQCC374X2201 Start Date*: 2017-07-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary art...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018369-48 Sponsor Protocol Number: CASTIP3 Start Date*: 2011-03-10
    Sponsor Name:Medizinische Universität Wien
    Full Title: Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherap...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004771-22 Sponsor Protocol Number: Vs.12.11-07-2008 Start Date*: 2008-09-03
    Sponsor Name:Rigshospitalet, Kardiologisk afd
    Full Title: Prospective randomised dubbleblind placebocontrolled trial of calcium antagonist to prevent calcineurin induced nephropathy in lung transplanted patients
    Medical condition: kidney damage in ciclosporin treated lung transplant patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029155 Nephropathy toxic PT
    14.1 10042613 - Surgical and medical procedures 10056409 Heart and lung transplant PT
    14.1 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004472-21 Sponsor Protocol Number: PCS_03_16 Start Date*: 2017-08-31
    Sponsor Name:Pieris Pharmaceuticals GmbH
    Full Title: Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease pa...
    Medical condition: Anemia of chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002752-34 Sponsor Protocol Number: Clin-AGI003-001 Start Date*: 2004-12-20
    Sponsor Name:AGI Therapeutics Limited
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.
    Medical condition: Irritable bowel syndrome (not constipation predominant).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023003 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002104-40 Sponsor Protocol Number: BAY63-2521/16097 Start Date*: 2013-03-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in ...
    Medical condition: Chronic Trombo Embolic Pulmonary Hypertention
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PT (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) NL (Completed) IT (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001702-88 Sponsor Protocol Number: 011-007 Start Date*: 2006-08-07
    Sponsor Name:Novacea, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
    Medical condition: For the treatment of metastatic androgen independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) HU (Prematurely Ended) CZ (Completed) SK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 11:04:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA